/

Ricerca sul cancro

/

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

JoVE Journal
Ricerca sul cancro

This content is Free Access.

JoVE Journal Ricerca sul cancro

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

3,552 Views

•

08:52 min

•

November 22, 2021

DOI:

10.3791/63039-v

DOI:

10.3791/63039-v

•

08:52 min

November 22, 2021

•

6 Views

Dora Barbosa Rabago^1,2,3, Collin M. Blakely^1,2, Franziska Haderk^1,2,3, Trever G. Bivona^1,2,3

¹Department of Medicine,University of California, San Francisco, ²Helen Diller Family Comprehensive Cancer Center,University of California, San Francisco, ³Department of Cellular and Molecular Pharmacology,University of California, San Francisco

Summary

This protocol describes a standardized evaluation of drug sensitivities to targeted signaling inhibitors in NSCLC patient-derived organoid models.

Explore More Videos

Organoids EGFR-mutant NSCLC Targeted Therapies Matrigel Cell Culture Dissociation Trypsinization Centrifugation Cell Counting Cell Suspension 96-well Plate

Read Article